Stellar Biotechnologies (SBOT) Receives Media Impact Score of 0.19

Media stories about Stellar Biotechnologies (NASDAQ:SBOT) have been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Stellar Biotechnologies earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 48.7369692527559 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the media stories that may have impacted Accern Sentiment’s rankings:

Get Stellar Biotechnologies alerts: 200 days simple moving average (SMA200) to Watch Flotek Industries, Inc. (NYSE:FTK), Stellar Biotechnologies, Inc … (stocksnewspoint.com) Morning Stocks You Can’t Afford to Pass Up:: Freeport-McMoRan Inc. (NYSE:FCX), Stellar Biotechnologies, Inc … (journalfinance.net) Should Investors Adjust Their Holdings in Stellar Biotechnologies, Inc. (NasdaqCM:SBOT)? Target Weight Stands at … (bedfordnewsjournal.com) Bright Stocks in Review: Bank of America Corporation (NYSE:BAC), Stellar Biotechnologies, Inc. (NASDAQ:SBOT … (journalfinance.net) Notable News Review: Telefonica, SA, (NYSE: TEF), Stellar Biotechnologies, Inc., (NASDAQ: SBOT) (globalexportlines.com)

Separately, ValuEngine upgraded shares of Stellar Biotechnologies from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 8th.

Stellar Biotechnologies traded down $0.01, hitting $1.86, during midday trading on Monday, Marketbeat reports. The company’s stock had a trading volume of 262,900 shares, compared to its average volume of 656,707. Stellar Biotechnologies has a 12 month low of $1.65 and a 12 month high of $10.85. The stock has a market cap of $6.17 million, a PE ratio of -0.54 and a beta of 0.22.

Stellar Biotechnologies Company Profile

Stellar Biotechnologies, Inc, a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market.